Neurocrine Biosciences Inc 's Cash & cash equivalent grew by 89.27 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Neurocrine Biosciences Inc 's Quick Ratio to 0.59, Quick Ratio remained below Neurocrine Biosciences Inc average.

Within Biotechnology & Pharmaceuticals industry 128 other companies have achieved higher Quick Ratio than Neurocrine Biosciences Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1347 to 2693.

Explain Quick Ratio?
How much Cash & cash equivalents NBIX�s has?
What are NBIX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NBIX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	94.8 %	91.49 %	59.06 %	16.33 %	48.48 %
Y / Y Cash & cash equivalent Change	-33.7 %	-59.97 %	39.5 %	37.57 %	-9.22 %
Quick Ratio MRQ	0.59	0.37	1.58	1.82	1.75
NBIX's Total Ranking	# 2693	# 1347	# 657	# 1052	#
Seq. Current Liabilities Change	18.8 %	25.78 %	2.5 %	27.18 %	16.79 %
Seq. Cash & cash equivalent Change	89.27 %	-70.33 %	-11.09 %	32.8 %	14.27 %

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 129
Healthcare Sector	# 757
Overall Market	# 2693

Quick Ratio Statistics
High	Average	Low
24.36	7.26	0.37
(Mar 31 2015)		(Jun 30 2026)

Financial Statements
Neurocrine Biosciences Inc 's Current Liabilities	$ 1,243 Millions	Visit NBIX's Balance sheet
Neurocrine Biosciences Inc 's Cash & cash equivalent	$ 739 Millions	Visit NBIX's Balance sheet
Source of NBIX's Sales		Visit NBIX's Sales by Geography

Cumulative Neurocrine Biosciences Inc 's Quick Ratio

NBIX's Quick Ratio for the trailling 12 Months

NBIX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	63.51 %	51.48 %	38.02 %	12.51 %	3.79 %
Y / Y Cash & cash equivalent TTM Growth	-4.47 %	1.86 %	14.01 %	-0.86 %	-8.85 %
Quick Ratio TTM	1	1.29	1.73	1.79	1.71
Total Ranking TTM	# 3959	# 3098	# 2087	# 2856	#
Seq. Current Liabilities TTM Growth	18.18 %	17.68 %	12.26 %	4.74 %	9.48 %
Seq. Cash & cash equivalent TTM Growth	-8.73 %	-11.97 %	8.26 %	9.84 %	-2.68 %

Quick ratio ranking by company, industry and sector >> Back to NBIX Financial Strength Comparisons >> Go to Compare NBIX Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $1,242.80 millions, cumulative Quick Ratio decreased to 1 below the Neurocrine Biosciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Neurocrine Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3098 to 3959.

Explain Quick Ratio?
How much Cash & cash equivalents NBIX�s has?
What are NBIX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 142
Healthcare Sector	# 890
Within the Market	# 3959

trailing twelve months Quick Ratio Statistics
High	Average	Low
19.43	7.49	1.39
(Sep 30 2015)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Sana Biotechnology Inc	1.63	$ 121.728 Millions	$ 74.880 Millions
Aligos Therapeutics Inc	1.59	$ 31.094 Millions	$ 19.600 Millions
Tarsus Pharmaceuticals Inc	1.36	$ 309.612 Millions	$ 227.114 Millions
Amgen Inc	1.11	$ 25,811.000 Millions	$ 23,231.000 Millions
Sab Biotherapeutics Inc	0.98	$ 14.438 Millions	$ 14.798 Millions
Bio techne Corp	0.97	$ 350.036 Millions	$ 361.269 Millions
C4 Therapeutics Inc	0.81	$ 33.492 Millions	$ 41.460 Millions
Allogene Therapeutics Inc	0.76	$ 29.270 Millions	$ 38.498 Millions
Ocugen Inc	0.71	$ 84.257 Millions	$ 118.901 Millions
Neurocrine Biosciences Inc	0.59	$ 739.100 Millions	$ 1,242.800 Millions
Iovance Biotherapeutics inc	0.55	$ 57.934 Millions	$ 105.774 Millions
Agenus Inc	0.43	$ 86.936 Millions	$ 203.691 Millions
Vaxcyte Inc	0.42	$ 125.470 Millions	$ 295.697 Millions
Vaxart Inc	0.41	$ 30.435 Millions	$ 73.934 Millions
Biogen Inc	0.16	$ 628.100 Millions	$ 3,898.400 Millions

Date modified: 2026-11-03T10:01:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.